key: cord-0951482-dkcewz6s
authors: Speeckaert, Marijn M; Delanghe, Joris R
title: Letter to the Editor from Speeckaert et al: “Vitamin D Deficiency Is Associated With Higher Hospitalization Risk from COVID-19: a Retrospective Case-control Study”
date: 2021-09-16
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgab606
sha: 142061eff64d744b0c4059a0dc3d8e75f7a8314b
doc_id: 951482
cord_uid: dkcewz6s

nan

With interest, we read the paper of Jude et al (1) , which investigated the role of vitamin D in the severity of COVID-19. In detail, vitamin D insufficiency or deficiency was associated with a 2.3 to 3.6 times higher risk of SARS-CoV-2 infection necessitating hospital admission. We would like to stress the potential influence of vitamin D binding protein (DBP) polymorphisms on the reported results.

Vitamin D and its metabolites are mainly bound to a specific transport protein, DBP, or group-specific component globulin (Gc-globulin), and in a minor fraction to albumin. More specifically, 88% of circulating 25(OH)-vitamin D 3 and 85% of 1,25(OH) 2 -vitamin D 3 is bound to DBP, whereas 10% to 15% is bound to albumin. DBP is a polymorphic plasma protein, which is characterized by 3 major alleles (DBP1F [rs7041-T/rs4588-C], DBP1S [rs7041-G/ rs4588-C], and DBP2 [rs7041-T/rs4588-A]) with the following phenotypes: DBP1-1 (DBP1F-1F, DBP1F-1S, and DBP1S-1S), DBP2-1 (DBP2-1F and DBP2-1S), and DBP2-2 (DBP2-2), and with more than 120 unique variants. Focusing on the potential association between DBP polymorphisms and COVID-19, a correlation between the rs7041 polymorphism and COVID-19 prevalence and mortality has been suggested (4). We have demonstrated that a higher country-specific DBP1 allele frequency is linked to a lower prevalence and mortality due to a SARS-CoV-2 infection, which could be partly explained by the potential protective effects of vitamin D and DBP (5) . As DBP2 carriers may be more predisposed to vitamin D insufficiency relative to individuals with DBP1 isoforms, the former group may have higher odds of severe SARS-CoV-2 infection necessitating hospital admission. Vitamin D deficiency appears to contribute to the development of acute respiratory distress syndrome (ARDS) (6) , which is one of the common clinical manifestations of severe COVID-19. In addition, a 30% reduction in plasma DBP in patients with ARDS supports a role for either reduced production or increased losses. Actin released from damaged cells is removed from the circulation by the extracellular actin-scavenger system, consisting of gelsolin and DBP. Gelsolin forms 1:2 molar complexes with filamentous, polymeric (F-)actin and stimulates its depolymerization, whereas DBP binds globular, monomeric (G-)actin and inhibits filament formation. The DBP-actin complexes are removed from the circulation by the reticuloendothelial system, primarily in the liver (7) . So, patients with lower serum DBP levels, especially the DBP2allele carriers, may consequently be more prone to endothelial damage. This can play an early and central pathogenic role in the development of ARDS and thrombosis during COVID-19 (8) .

In conclusion, we suggest taking DBP polymorphisms into account in the evaluation of vitamin D concentrations in COVID-19 patients.

Vitamin D deficiency is associated with higher hospitalization risk from COVID-19: a retrospective case-control study

Vitamin D binding protein: a multifunctional protein of clinical importance

Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration

The role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate

Vitamin D binding protein polymorphism and COVID-19

Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)

Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism

Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab